Daiichi Sankyo And AstraZeneca's ENHERTU Receives Breakthrough Therapy Designation In The U.S. For Specific Patients With HER2 Low Or Ultralow Metastatic Breast Cancer
Portfolio Pulse from Benzinga Newsdesk
Daiichi Sankyo and AstraZeneca's ENHERTU has received its eighth Breakthrough Therapy Designation from the FDA for treating specific patients with HER2 low or ultralow metastatic breast cancer. This designation is based on the results of the DESTINY-Breast06 phase 3 trial.
August 19, 2024 | 6:29 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AstraZeneca's ENHERTU has received its eighth Breakthrough Therapy Designation from the FDA, which could lead to accelerated approval and increased market potential.
The Breakthrough Therapy Designation can expedite the development and review process, potentially leading to faster market entry and increased sales for AstraZeneca.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Daiichi Sankyo's ENHERTU has received its eighth Breakthrough Therapy Designation from the FDA, enhancing its prospects in the oncology market.
The FDA's Breakthrough Therapy Designation can accelerate the approval process, potentially leading to increased market share and revenue for Daiichi Sankyo.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100